Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4010
-0.01-2.67%
At close: -
$0.3900
-0.01-2.74%
After Hours: May 16, 6:31 PM EDT
Comments
Loading...
Leap Therapeutics Analyst Ratings and Price Targets | NASDAQ:LPTX | Benzinga
Leap Therapeutics Inc has a consensus price target of $11.63 based on the ratings of 5 analysts. The high is $17.5 issued by Raymond James on November 14, 2023. The low is $8 issued by Rodman & Renshaw on June 28, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on January 16, 2025, November 15, 2024, and August 13, 2024, respectively. With an average price target of $5.5 between HC Wainwright & Co., there's an implied 1310.26% upside for Leap Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Rodman & Renshaw
Baird
Mizuho
Raymond James
1calculated from analyst ratings
Analyst Ratings for Leap Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/27/2025 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth50% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/29/2025 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth50% | — | Downgrade | Buy → Neutral | Get Alert |
| 01/16/2025 | Buy Now | 1310.26% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $5.5 → $5.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 1310.26% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $5.5 → $5.5 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 1310.26% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $5.5 → $5.5 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 1951.28% | Rodman & Renshaw | Tony Butler42% | → $8 | Initiates | → Buy | Get Alert |
| 05/14/2024 | Buy Now | 1310.26% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $7 → $5.5 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | 1694.87% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | 2207.69% | Baird | Joel Beatty65% | $11 → $9 | Maintains | Outperform | Get Alert |
| 11/20/2023 | Buy Now | 2976.92% | Mizuho | Mara Goldstein56% | $20 → $12 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 4387.18% | Raymond James | Steven Seedhouse57% | $18.5 → $17.5 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 5028.21% | Baird | Joel Beatty65% | $30 → $20 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 1694.87% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $2.5 → $7 | Maintains | Buy | Get Alert |
| 07/13/2023 | Buy Now | 4643.59% | Raymond James | Steven Seedhouse57% | $17 → $18.5 | Maintains | Outperform | Get Alert |
| 06/23/2023 | Buy Now | 4258.97% | Raymond James | Steven Seedhouse57% | $20 → $17 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | 541.03% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $2.5 | Reiterates | Buy → Buy | Get Alert |
| 04/13/2023 | Buy Now | 412.82% | Mizuho | Mara Goldstein56% | → $2 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | 541.03% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $2.5 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | 412.82% | Raymond James | Steven Seedhouse57% | $2.5 → $2 | Maintains | Outperform | Get Alert |
| 03/17/2023 | Buy Now | 412.82% | Mizuho | Mara Goldstein56% | $3 → $2 | Maintains | Buy | Get Alert |
| 01/27/2023 | Buy Now | 669.23% | Mizuho | Mara Goldstein56% | $6 → $3 | Maintains | Buy | Get Alert |
| 01/18/2023 | Buy Now | 541.03% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $4 → $2.5 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 541.03% | Raymond James | Steven Seedhouse57% | $3.5 → $2.5 | Maintains | Outperform | Get Alert |
| 08/15/2022 | Buy Now | 797.44% | Raymond James | Steven Seedhouse57% | $3 → $3.5 | Maintains | Outperform | Get Alert |
| 07/13/2022 | Buy Now | 669.23% | Raymond James | Steven Seedhouse57% | $4 → $3 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Leap Therapeutics (LPTX) stock?
The latest price target for Leap Therapeutics (NASDAQ:LPTX) was reported by HC Wainwright & Co. on March 27, 2025. The analyst firm set a price target for $0.00 expecting LPTX to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Leap Therapeutics (LPTX)?
The latest analyst rating for Leap Therapeutics (NASDAQ:LPTX) was provided by HC Wainwright & Co., and Leap Therapeutics reiterated their neutral rating.
When was the last upgrade for Leap Therapeutics (LPTX)?
There is no last upgrade for Leap Therapeutics
When was the last downgrade for Leap Therapeutics (LPTX)?
The last downgrade for Leap Therapeutics Inc happened on January 29, 2025 when HC Wainwright & Co. changed their price target from N/A to N/A for Leap Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Leap Therapeutics (LPTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on March 27, 2025 so you should expect the next rating to be made available sometime around March 27, 2026.
Is the Analyst Rating Leap Therapeutics (LPTX) correct?
While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Leap Therapeutics (LPTX) is trading at is $0.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
